A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Eli Lilly revenue surged in the latest quarter on steady sales of Mounjaro and other weight-loss treatments in its portfolio.

Ricks said reshoring manufacturing capacity for older essential medicines is “a valid thing,” adding that Eli Lilly is “happy ...

Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro soared in the first quarter.

Investors are betting that Lilly will maintain its momentum. Its share price has climbed by a third since the start of 2024; Novo’s has fallen by as much (see chart 2). Lilly’s edge rests on a more ...

Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an ...

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to ...

The new research and development site will combine research, process development and clinical trial manufacturing ...

We recently published an article titled Jim Cramer Says AI Is Back & Discusses These 10 Stocks. In this article, we are going ...

Eli Lilly and Company (NYSE: LLY) shares are trading lower Tuesday. The stock appears to be moving in reaction to an ...

Eli Lilly and Company became the first tenant to move into Lebanon’s LEAP district during a groundbreaking ceremony on ...